Genetic polymorphism atBCL2as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.
Department of Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.|Dalla Lana School of Public Health, University of Toronto, ON, Canada.
Morteza
M
Bashash
Division of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.|Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada.
Joseph M
JM
Connors
Department of Pathology, BC Cancer Agency, Vancouver, BC, Canada.|Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada.
Randy D
RD
Gascoyne
Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada.
Barbara
B
Meissner
Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
Johanna M
JM
Schuetz
Department of Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
Stephen
S
Leach
Department of Pathology, BC Cancer Agency, Vancouver, BC, Canada.|Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada.
Graham W
GW
Slack
Department of Pathology, Royal Jubilee Hospital, Victoria, BC, Canada.
Brian R
BR
Berry
Dalla Lana School of Public Health, University of Toronto, ON, Canada.
Howard
H
Hu
Division of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.|Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada.
Laurie H
LH
Sehn
Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.|Department of Pathology, Royal Jubilee Hospital, Victoria, BC, Canada.|Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
Angela R
AR
Brooks-Wilson
Department of Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada jspinelli@bccrc.ca.|School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
John J
JJ
Spinelli
D000483:Alleles; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D058846:Antibodies, Monoclonal, Murine-Derived; D019253:Proto-Oncogene Proteins c-bcl-2; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone